Anthony Turkiewicz

Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

John H. Stone, Peter A. Merkel, Robert Spiera et al. · New England Journal of Medicine · 2010 · 2.7K citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritis

Kenneth G. Saag, Gim Gee Teng, Nivedita M. Patkar et al. · Arthritis Care & Research · 2008 · 1.5K citations

Medicine, Pharmacotherapy, Clinical Medicine +11

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

Peter Nash, Bruce Kirkham, Masato Okada et al. · The Lancet · 2017 · 405 citations · Full text

Medicine, Immunology, Pharmacotherapy +13

4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis

Désirée van der Heijde, Atul Deodhar, Oliver FitzGerald et al. · RMD Open · 2018 · 48 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +13

Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure

Philip J. Mease, Atul Deodhar, Roy Fleischmann et al. · RMD Open · 2015 · 45 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16